...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
【24h】

Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.

机译：在转移性结直肠癌中，伊立替康/氟尿嘧啶/亚叶酸或相同的方案，然后是奥沙利铂/氟尿嘧啶/亚叶酸。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy. MATERIALS AND METHODS: Intent-to-treat analysis was performed on 417 patients (211 in arm A and 206 in arm B). Treatment schedules of weekly IRI 80 mg/m(2) or OXA 45 mg/m(2) plus LV 200 mg/m(2) immediately followed by intravenous bolus FU 450 mg/m(2) for 6 weeks were followed by a 2-week rest period. Treatment continued for 4 cycles. Patients in arm A were treated with IRI/FU/LV for 4 cycles, while patients in arm B were initially treated with IRI/FU/LV for 2 cycles followed by sequential administration of 2 cycles of OXA/FU/LV. RESULTS: No significant difference emerged in overall response rate or overall survival. There was a difference in progression-free survival (median, 7.3 versus 8.2 months, p=0.040) in favour of arm B. Toxicity profiles were similar in both arms. CONCLUSION: IRI/FU/LV and IRI/FU/LV followed by OXA/FU/LV showed comparable activity with a manageable toxicity profile.
机译：背景：这项研究报告了一项转移性大肠癌（CRC）患者的长期随访，该患者参加了一项随机II期研究，该研究比较了伊立替康（IRI），氟尿嘧啶（FU）与亚叶酸（联合）的疗效和毒性。 LV）（A组）与先后联合IRI加FU / LV，奥沙利铂（OXA）加FU / LV（B组）的序贯化疗。材料与方法：对417例患者进行意向治疗分析（A组211例，B组206例）。每周IRI 80 mg / m（2）或OXA 45 mg / m（2）加LV 200 mg / m（2）的治疗方案应立即进行，然后静脉推注FU 450 mg / m（2），持续6周。 2周的休息时间。治疗持续4个周期。 A组患者接受IRI / FU / LV治疗4个周期，而B组患者最初接受IRI / FU / LV治疗2个周期，然后依次给药2个周期的OXA / FU / LV。结果：总体缓解率或总体生存率无明显差异。 B组的无进展生存期存在差异（中位7.3与8.2个月，p = 0.040）。两组的毒性反应相似。结论：IRI / FU / LV和IRI / FU / LV，然后是OXA / FU / LV，具有可比的活性，且毒性可控。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号